Skip to main content

Advertisement

SpringerLink
Log in

Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes

  • Retina (R Goldhardt, Section Editor)
  • Published:
Current Ophthalmology Reports Aims and scope Submit manuscript

A Correction to this article was published on 13 July 2020

This article has been updated

Abstract

Purpose of Review

To summarize the available literature on retinal imaging metrics in the context of intravitreal injections in glaucomatous and non-glaucomatous eyes.

Recent Findings

The retinal nerve fiber layer (RNFL) in injected non-glaucomatous eyes appears to thin at a similar rate to uninjected fellow eyes. A total of four studies evaluating RNFL thinning in injected glaucomatous eyes yielded mixed results, with more recent longitudinal investigations suggesting a potential association. The ganglion cell-inner plexiform layer is also being studied as a potential endpoint in both glaucomatous and non-glaucomatous eyes following intravitreal injections.

Summary

There appears to be minimal association between intravitreal injections and RNFL thinning among non-glaucomatous eyes. However, in glaucomatous eyes, fewer studies have been published, and results have varied due to challenges in study design. Additional prospective studies with longer follow-up periods are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 13 July 2020

    The original version of this article unfortunately contained a mistake.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Quigley HA. Glaucoma. Lancet (Lond). 2011;377(9774):1367–77. https://doi.org/10.1016/s0140-6736(10)61423-7.

    Article  Google Scholar 

  2. Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest Ophthalmol Vis Sci. 2013;54(14):Orsf5–orsf13. https://doi.org/10.1167/iovs.13-12789.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bourne RRA, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br J Ophthalmol. 2014;98(5):629–38. https://doi.org/10.1136/bjophthalmol-2013-304033.

  4. Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 update on Intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181–93. https://doi.org/10.1159/000486145.

  5. Hoguet A, Chen PP, Junk AK, Mruthyunjaya P, Nouri-Mahdavi K, Radhakrishnan S, et al. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2019;126(4):611–22. https://doi.org/10.1016/j.ophtha.2018.11.019.

  6. Kiddee W, Montriwet M. Intraocular pressure changes in non-glaucomatous patients receiving Intravitreal anti-vascular endothelial growth factor agents. PLoS One. 2015;10(9):e0137833. https://doi.org/10.1371/journal.pone.0137833.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jain P, Sheth J, Anantharaman G, Gopalakrishnan M. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian J Ophthalmol. 2017;65(7):596–602. https://doi.org/10.4103/ijo.IJO_992_16.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(6):930–4.e1. https://doi.org/10.1016/j.ajo.2008.07.007.

    Article  CAS  PubMed  Google Scholar 

  9. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21(3):178–83. https://doi.org/10.1097/ICU.0b013e328338679a.

    Article  PubMed  Google Scholar 

  10. Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32(7):1295–301. https://doi.org/10.1097/IAE.0b013e31823f0c95.

    Article  CAS  PubMed  Google Scholar 

  11. Wingard JB, Delzell DA, Houlihan NV, Lin J, Gieser JP. Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration. Clin Ophthalmol. 2019;13:2563–72. https://doi.org/10.2147/opth.S232548.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010;26(1):105–10. https://doi.org/10.1089/jop.2009.0076.

    Article  CAS  PubMed  Google Scholar 

  13. Atchison EA, Wood KM, Mattox CG, Barry CN, Lum F, MacCumber MW. The real-world effect of Intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry. Ophthalmology. 2018;125(5):676–82. https://doi.org/10.1016/j.ophtha.2017.11.027.

    Article  PubMed  Google Scholar 

  14. Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol. 2016;35(4):310–4. https://doi.org/10.3109/15569527.2015.1124886.

    Article  CAS  PubMed  Google Scholar 

  15. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009;23(1):181–5. https://doi.org/10.1038/sj.eye.6702938.

    Article  CAS  Google Scholar 

  16. Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: what is the evidence? Retina. 2015;35(5):841–58. https://doi.org/10.1097/iae.0000000000000520.

    Article  CAS  PubMed  Google Scholar 

  17. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95(8):1111–4. https://doi.org/10.1136/bjo.2010.180729.

    Article  PubMed  Google Scholar 

  18. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119(2):321–6. https://doi.org/10.1016/j.ophtha.2011.08.011.

    Article  PubMed  Google Scholar 

  19. Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012;21(4):241–7. https://doi.org/10.1097/IJG.0b013e31820d7d19.

  20. Demirel S, Batioglu F, Ozmert E, Erenler F. The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr Eye Res. 2015;40(1):87–92. https://doi.org/10.3109/02713683.2014.917190.

    Article  CAS  PubMed  Google Scholar 

  21. Horsley MB, Mandava N, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150(4):558–61.e1. https://doi.org/10.1016/j.ajo.2010.04.029.

    Article  CAS  PubMed  Google Scholar 

  22. Shin HJ, Shin KC, Chung H, Kim HC. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2014;55(4):2403–11. https://doi.org/10.1167/iovs.13-13769.

    Article  PubMed  Google Scholar 

  23. Sobaci G, Gungor R, Ozge G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol. 2013;6(2):211–5. https://doi.org/10.3980/j.issn.2222-3959.2013.02.20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Parlak M, Oner FH, Saatci AO. The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration. Int Ophthalmol. 2015;35(4):473–80. https://doi.org/10.1007/s10792-014-9972-2.

    Article  PubMed  Google Scholar 

  25. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2012;53(10):6214–8. https://doi.org/10.1167/iovs.12-9875.

  26. • Shin HJ, Kim S-N, Chung H, Kim T-E, Kim HC. Intravitreal anti–vascular endothelial growth factor therapy and retinal nerve fiber layer loss in eyes with age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci. 2016;57(4):1798–806. This meta analysis evaluated all available literature at time of publication regarding RNFL thickness following intravitreal injections https://doi.org/10.1167/iovs.15-18404.

  27. Beck M, Munk MR, Ebneter A, Wolf S, Zinkernagel MS. Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol. 2016;167:10–7. https://doi.org/10.1016/j.ajo.2016.04.003.

    Article  CAS  PubMed  Google Scholar 

  28. Jo YJ, Kim WJ, Shin IH, Kim JY. Longitudinal changes in retinal nerve fiber layer thickness after intravitreal anti-vascular endothelial growth factor therapy. Korean J Ophthalmol. 2016;30(2):114–20. https://doi.org/10.3341/kjo.2016.30.2.114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zhang Z, Yang X, Jin H, Qu Y, Zhang Y, Liu K, et al. Changes in retinal nerve fiber layer thickness after multiple injections of novel VEGF decoy receptor conbercept for various retinal diseases. Sci Rep. 2016;6:38326. https://doi.org/10.1038/srep38326.

  30. Zucchiatti I, Cicinelli MV, Parodi MB, Pierro L, Gagliardi M, Accardo A, et al. Effect of intravitreal ranibizumab on ganglion cell complex and peripapillary retinal nerve fiber layer in neovascular age-related macular degeneration using spectral domain optical coherence tomography. Retina. 2017;37(7):1314–9. https://doi.org/10.1097/iae.0000000000001360.

    Article  CAS  PubMed  Google Scholar 

  31. Gomez-Mariscal M, Puerto B, Munoz-Negrete FJ, de Juan V, Rebolleda G. Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2221–31. https://doi.org/10.1007/s00417-019-04354-7.

    Article  CAS  PubMed  Google Scholar 

  32. Valverde-Megias A, Ruiz-Calvo A, Murciano-Cespedosa A, Hernandez-Ruiz S, Martinez-de-la-Casa JM, Garcia-Feijoo J. Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1459–66. https://doi.org/10.1007/s00417-019-04325-y.

    Article  CAS  PubMed  Google Scholar 

  33. Acharya NR, Sittivarakul W, Qian Y, Hong KC, Lee SM. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina. 2011;31(9):1871–6. https://doi.org/10.1097/IAE.0b013e318213da43.

    Article  CAS  PubMed  Google Scholar 

  34. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695.e1–15. https://doi.org/10.1016/j.ophtha.2006.05.064.

    Article  Google Scholar 

  35. Gu X, Yu X, Dai H. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res. 2014;39(5):518–21. https://doi.org/10.3109/02713683.2013.848899.

    Article  CAS  PubMed  Google Scholar 

  36. Hanhart J, Tiosano L, Averbukh E, Banin E, Hemo I, Chowers I. Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye (Lond). 2014;28(6):646–53. https://doi.org/10.1038/eye.2014.94.

    Article  CAS  Google Scholar 

  37. Meyer CH, Krohne TU, Holz FG. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol. 2012;90(1):68–70. https://doi.org/10.1111/j.1755-3768.2009.01842.x.

    Article  CAS  PubMed  Google Scholar 

  38. Velez-Montoya R, Fromow-Guerra J, Burgos O, Landers MB 3rd, Morales-Caton V, Quiroz-Mercado H. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina. 2009;29(1):20–6. https://doi.org/10.1097/IAE.0b013e318186c64e.

    Article  PubMed  Google Scholar 

  39. Lee EK, Yu HG. Ganglion cell–inner plexiform layer and peripapillary retinal nerve fiber layer thicknesses in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56(6):3976–83. https://doi.org/10.1167/iovs.15-17013.

    Article  CAS  PubMed  Google Scholar 

  40. Lee WJ, Baek SU, Kim YK, Park KH, Jeoung JW. Rates of ganglion cell-inner plexiform layer thinning in normal, open-angle glaucoma and pseudoexfoliation glaucoma eyes: a trend-based analysis. Invest Ophthalmol Vis Sci. 2019;60(2):599–604. https://doi.org/10.1167/iovs.18-25296.

    Article  CAS  PubMed  Google Scholar 

  41. Scuderi G, Fragiotta S, Scuderi L, Iodice CM, Perdicchi A. Ganglion cell complex analysis in glaucoma patients: what can it tell us? Eye Brain. 2020;12:33–44. https://doi.org/10.2147/eb.S226319.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Shin HY, Park HY, Jung KI, Park CK. Comparative study of macular ganglion cell-inner plexiform layer and peripapillary retinal nerve fiber layer measurement: structure-function analysis. Invest Ophthalmol Vis Sci. 2013;54(12):7344–53. https://doi.org/10.1167/iovs.13-12667.

    Article  PubMed  Google Scholar 

  43. Shin JW, Sung KR, Lee GC, Durbin MK, Cheng D. Ganglion cell-inner plexiform layer change detected by optical coherence tomography indicates progression in advanced glaucoma. Ophthalmology. 2017;124(10):1466–74. https://doi.org/10.1016/j.ophtha.2017.04.023.

    Article  PubMed  Google Scholar 

  44. Shin JW, Sung KR, Park SW. Patterns of progressive ganglion cell-inner plexiform layer thinning in glaucoma detected by OCT. Ophthalmology. 2018;125(10):1515–25. https://doi.org/10.1016/j.ophtha.2018.03.052.

    Article  PubMed  Google Scholar 

  45. Koh KM, Jin S, Hwang YH. Cirrus high-definition optical coherence tomography versus spectral optical coherence tomography/scanning laser ophthalmoscopy in the diagnosis of glaucoma. Curr Eye Res. 2014;39(1):62–8. https://doi.org/10.3109/02713683.2013.824989.

    Article  CAS  PubMed  Google Scholar 

  46. Leite MT, Rao HL, Zangwill LM, Weinreb RN, Medeiros FA. Comparison of the diagnostic accuracies of the spectralis, cirrus, and RTVue optical coherence tomography devices in glaucoma. Ophthalmology. 2011;118(7):1334–9. https://doi.org/10.1016/j.ophtha.2010.11.029.

    Article  PubMed  Google Scholar 

  47. Smretschnig E, Krebs I, Moussa S, Ansari-Shahrezaei S, Binder S. Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment. Graefes Arch Clin Exp Ophthalmol. 2010;248(12):1693–8. https://doi.org/10.1007/s00417-010-1415-9.

    Article  PubMed  Google Scholar 

  48. • Kopic A, Biuk D, Barac J, Vinkovic M, Benasic T, Kopic V. Retinal nerve fiber layer thickness in glaucoma patients treated with multiple intravitreal anti-VEGF (bevacizumab) injections. Acta Clin Croat. 2017;56(3):406–14. This article is a prospective study that studied intravitreal injections in glaucomatous eyes https://doi.org/10.20471/acc.2017.56.03.07.

  49. Bonyadi M, Mohammadian T, Jabbarpoor Bonyadi MH, Fotouhi N, Soheilian M, Javadzadeh A, et al. Association of polymorphisms in complement component 3 with age-related macular degeneration in an Iranian population. Ophthalmic Genet. 2017;38(1):61–6. https://doi.org/10.3109/13816810.2015.1126612.

  50. Goto A, Akahori M, Okamoto H, Minami M, Terauchi N, Haruhata Y, et al. Genetic analysis of typical wet-type age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese population. J Ocul Biol Dis Infor. 2009;2(4):164–75. https://doi.org/10.1007/s12177-009-9047-1.

  51. Toomey CB, Johnson LV, Bowes RC. Complement factor H in AMD: bridging genetic associations and pathobiology. Prog Retin Eye Res. 2018;62:38–57. https://doi.org/10.1016/j.preteyeres.2017.09.001.

    Article  CAS  PubMed  Google Scholar 

  52. Griffith JF, Goldberg JL. Prevalence of comorbid retinal disease in patients with glaucoma at an academic medical center. Clin Ophthalmol. 2015;9:1275–84. https://doi.org/10.2147/opth.S85851.

    Article  PubMed  PubMed Central  Google Scholar 

  53. • Lee WJ, Kim YK, Kim YW, Jeoung JW, Kim SH, Heo JW, et al. Rate of macular ganglion cell-inner plexiform layer thinning in glaucomatous eyes with vascular endothelial growth factor inhibition. J Glaucoma. 2017;26(11):980–6. This study is significant for its evaluation of both GCIPL and RNFL in glaucomatous eyes following intravitreal injections https://doi.org/10.1097/ijg.0000000000000776.

  54. • Saleh R, Karpe A, Zinkernagel MS, Munk MR. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):817–24. https://doi.org/10.1007/s00417-017-3590-4.

    Article  CAS  PubMed  Google Scholar 

  55. • Du J, Patrie JT, Prum BE, Netland PA, Shildkrot YE. Effects of Intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2019;28(12):1035–40. This study demonstrated statistically significant changes in RNFL after intravitreal injections in glaucomatous eyes https://doi.org/10.1097/ijg.0000000000001382.

  56. Park CH, Lee KI, Park HY, Lee JH, Kim IT, Park CK. Changes in the retinal nerve fiber layer after intravitreal injections of bevacizumab in glaucoma patients. J Korean Ophthalmol Soc. 2014;55(5):693–701.

    Article  Google Scholar 

  57. Rud'ko AS, Budzinskaya MV, Andreeva IV, Karpilova MA, Smirnova TV. Effect of intravitreal injections of ranibizumab and aflibercept on the retinal nerve fiber layer in patients with concomitant neovascular age-related macular degeneration and glaucoma. Vestn oftalmol. 2019;135(5. Vyp. 2):177–83. https://doi.org/10.17116/oftalma2019135052177.

    Article  CAS  PubMed  Google Scholar 

  58. Shin YI, Nam KY, Lee SE, Lim HB, Lee MW, Jo YJ, et al. Changes in peripapillary microvasculature and retinal thickness in the fellow eyes of patients with unilateral retinal vein occlusion: an OCTA study. Invest Ophthalmol Vis Sci. 2019;60(2):823–9. https://doi.org/10.1167/iovs.18-26288.

  59. Hwang DJ, Lee EJ, Lee SY, Park KH, Woo SJ. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles. Invest Ophthalmol Vis Sci. 2014;55(7):4213–9. https://doi.org/10.1167/iovs.13-13776.

    Article  PubMed  Google Scholar 

  60. Rimayanti U, Kiuchi Y, Yamane K, Latief MA, Mochizuki H, Hirata J, et al. Inner retinal layer comparisons of eyes with exudative age-related macular degeneration and eyes with age-related macular degeneration and glaucoma. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):563–70. https://doi.org/10.1007/s00417-013-2496-z.

    Article  PubMed  Google Scholar 

  61. Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol. 2012;23(2):105–10. https://doi.org/10.1097/ICU.0b013e32834ff41d.

    Article  PubMed  Google Scholar 

  62. Gregori NZ, Weiss MJ, Goldhardt R, Schiffman JC, Vega E, Mattis CA, et al. Ocular decompression with cotton swabs lowers intraocular pressure elevation after intravitreal injection. J Glaucoma. 2014;23(8):508–12. https://doi.org/10.1097/IJG.0b013e318294865c.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Ichiyama Y, Sawada T, Kakinoki M, Sawada O, Nakashima T, Saishin Y, et al. Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration. Ophthalmic Res. 2014;52(4):234–8. https://doi.org/10.1159/000365253.

    Article  CAS  PubMed  Google Scholar 

  64. Lam J, Luttrell I, Ding L, Rezaei K, Chao JR, Chee Y, et al. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection. Graefes Arch Clin Exp Ophthalmol. 2019;257(11):2489–94. https://doi.org/10.1007/s00417-019-04431-x.

    Article  CAS  PubMed  Google Scholar 

  65. Saxena S, Lai TY, Koizumi H, Farah ME, Ferrara D, Pelayes D, et al. Anterior chamber paracentesis during intravitreal injections in observational trials: effectiveness and safety and effects. Int J Retina Vitreous. 2019;5:8. https://doi.org/10.1186/s40942-019-0157-z.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Soheilian M, Karimi S, Montahae T, Nikkhah H, Mosavi SA. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefes Arch Clin Exp Ophthalmol. 2017;255(9):1705–12. https://doi.org/10.1007/s00417-017-3702-1.

    Article  CAS  PubMed  Google Scholar 

  67. Song S, Yu XB, Dai H. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: a case-control study. Indian J Ophthalmol. 2016;64(10):762–6. https://doi.org/10.4103/0301-4738.195006.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monatsbl Augenheilkd. 2010;227(4):280–4. https://doi.org/10.1055/s-0029-1245201.

    Article  CAS  PubMed  Google Scholar 

  69. Frenkel MPC, Haji SA, Frenkel REP. Effect of prophylactic intraocular pressure–lowering medication on intraocular pressure spikes after Intravitreal injections. Arch Ophthalmol. 2010;128(12):1523–7. https://doi.org/10.1001/archophthalmol.2010.297.

    Article  PubMed  Google Scholar 

  70. Enders P, Sitnilska V, Altay L, Schaub F, Muether PS, Fauser S. Retinal nerve fiber loss in anti-VEGF therapy for age-related macular degeneration can be decreased by anterior chamber paracentesis. Ophthalmologica. 2017;237(2):111–8. https://doi.org/10.1159/000457907.

    Article  PubMed  Google Scholar 

  71. Shah AP, Sisk RA, Foster RE. Complications of serial anterior chamber paracentesis for increased intraocular pressure after intravitreal injections. Retin Cases Brief Rep. 2019. https://doi.org/10.1097/icb.0000000000000939.

Download references

Funding

NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL, 33136, USA

    Ronaldo Nuesi & Swarup S. Swaminathan

  2. Herbert Wertheim College of Medicine, Florida International University, Miami, FL, 33199, USA

    Ronaldo Nuesi

Authors
  1. Ronaldo Nuesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Swarup S. Swaminathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Swarup S. Swaminathan.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: the sentence “Despite no clear correlation between intravitreal injections and retinal thinning, attempts have been made to mitigate the potential effects of post-injection IOP spikes [61].” was added back for it was deleted.

This article is part of the Topical Collection on Retina

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nuesi, R., Swaminathan, S.S. Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes. Curr Ophthalmol Rep 8, 111–119 (2020). https://doi.org/10.1007/s40135-020-00235-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40135-020-00235-z

Keywords

Search

Navigation